The Menopause-at-Work Market Followed the Playbook. The Playbook Was Wrong.
As PwC names menopause a defining women's health opportunity, Lozen Advisory issues a market correction on utilization failure and the false assumption that awareness equals adoption.
Atlanta, GA — May 19, 2026 — PwC has now named menopause as a defining opportunity in women's health. That recognition matters, it confirms that the market is no longer perceived as niche. Menopause is now projected to be a $15B–$25B market by 2030. Approximately $1.7 billion has already been deployed into menopause and midlife women's health platforms between 2020 and 2025, with funding events growing at roughly 15% annually, according to PwC.
Yet market expansion does not answer the question no one is asking: is the investment reaching the women it was designed for?
Lozen Advisory LLC today issued a market correction: the menopause-at-work market has treated awareness as adoption, access as reach, and utilization as proof of need. The data is exposing the failure.
"The menopause-at-work market built awareness and called it reach," said Akilah E. Kamaria, founder of Lozen Advisory LLC. "Employers can run campaigns, train managers, launch a ‘Let’s Talk Menopause’ initiative, and build a company ‘Menopause Hub’, and still have no reliable way to assess whether the investment is reaching the women it was designed for."
Employers have added benefits. Certification bodies have expanded. Government commissions have convened. Celebrity campaigns, TikTok, and medical influencers have moved menopause into the public conversation. Yet the central failure remains.
Women still do not understand the transition. Women still feel unprepared for the disruption. Women still are not using treatment and are dissatisfied with the available options. And, even as employers add more benefits, employee confidence that those benefits support them is falling.
Bonafide's fifth annual State of Menopause report delivers the five-year verdict: more products, more visibility, more market activity, and women still no closer to comprehension, treatment use, confidence, or trust. The report found that 59% of women ages 40 to 49 never knew about perimenopause until symptoms began, 71% feel unprepared for how disruptive symptoms are, 69% are not using any treatment for their symptoms, and 48% of women ages 40 to 49 report symptoms have negatively impacted their ambition.
That is not a market solving the problem. That is a market producing awareness without producing adoption.
Maven Clinic titled its 2026 State of Women's and Family Health Benefits report More Benefits, Less Confidence. The data behind that title is the market's admission. Employers increased women's and family health benefits by 39% year over year. Employee confidence that those benefits support them very well declined across every category.
The Michigan Women's Commission spent two years gathering one of the most substantial state-level menopause datasets in the country. Thousands of women. Thirteen community conversations. A statewide tour. The Menopause Memorandum released in March 2026 with recommendations to educate employees, train supervisors, and expand benefits. Yet not one recommendation addressed the woman who said no — the woman who would not use the support because using it required visibility she could not afford. The data saw her, but the recommendations did not.
Lozen Advisory says the reason is structural. The menopause-at-work market has treated awareness as the pathway to adoption. The assumption is simple: once women know what is happening, they will seek support; once employers offer support, women will use it; once women use it, utilization data will show whether the benefit works.
That assumption fails at the point of professional risk. "The market has confused awareness with adoption," Kamaria said. "A woman can understand the perimenopause transition, recognize the symptoms, and still decline to enter a system that logs her private constraint. That type of non-disclosure is not ignorance; it is a rational calculation inside a professional environment where visibility carries cost."
Kamaria built her career solving expensive data problems for major institutions across finance, healthcare, cybersecurity, and media. Lozen Advisory’s market correction comes from that experience. "The menopause-at-work market is built for the woman who raises her hand," Kamaria said. "The woman with the most to lose professionally was never going to raise hers."
That is the structural failure. The market has been asking and advising employers to offer menopause support. Can that support be used, trusted, and accessed by women who will not disclose? "The absence of utilization is not the absence of need," Kamaria said. "It may be evidence that the system cannot reach the women it claims to support."
The menopause-at-work benefit market is not failing because women didn’t understand the services. It is failing because the infrastructure was built around the raised hand.
Media Contact
Lozen Advisory LLC
media@lozenadvisory.com
lozenadvisory.com